UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Clinical lymphoma, myeloma and leukemia, 2021-11, Vol.21 (11), p.785-798

2021

Volltextzugriff (PDF)

Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation–Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study

Clinical lymphoma, myeloma and leukemia, 2019-11, Vol.19 (11), p.e605-e615

2019

Volltextzugriff (PDF)

MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S340

2022

Volltextzugriff (PDF)

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S339-S340

2022

Volltextzugriff (PDF)

Serum Free Light Chain Difference and β 2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis

Clinical lymphoma, myeloma and leukemia, 2018-06, Vol.18 (6), p.408-414

2018

Volltextzugriff (PDF)

Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing

Clinical lymphoma, myeloma and leukemia, 2019-08, Vol.19 (8), p.e496-e505

2019

Volltextzugriff (PDF)

P-217: First line daratumumab-VTd versus VRd for transplant eligible multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S154-S154a

2022

Volltextzugriff (PDF)

Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2012-04, Vol.12 (2), p.118-126

2012

Volltextzugriff (PDF)

P-200: Pomalidomide-based chemotherapy in plasmacytoma at relapse

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S148-S148

2021

Volltextzugriff (PDF)

P-429 Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S277-S277

2023

Volltextzugriff (PDF)

OA-25 Impact of Clonal Hematopoiesis on the Carcinogenic Process of Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S16-S17

2024

Volltextzugriff (PDF)

P-052 LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S63-S64

2023

Volltextzugriff (PDF)

P-135 Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean multiple myeloma working party (KMM 2202)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S109-S110

2023

Volltextzugriff (PDF)

Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e155-e156

2019

Volltextzugriff (PDF)

MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S572-S573

2024

Volltextzugriff (PDF)

OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S2-S3

2024

Volltextzugriff (PDF)

Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S244-S244

2024

Volltextzugriff (PDF)

P-284 Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S192-S193

2023

Volltextzugriff (PDF)

P-144 Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S115-S115

2023

Volltextzugriff (PDF)

P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S49-S50

2023

Volltextzugriff (PDF)

POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S226-S226

2023

Volltextzugriff (PDF)

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S478-S479

2023

Volltextzugriff (PDF)

Poster: MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S155

2022

Volltextzugriff (PDF)

Poster: MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S155

2022

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Lymphoma, Myeloma And Leukemia

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

Hematology
(8)
Life Sciences & Biomedicine
(8)
Oncology
(8)
Science & Technology
(8)
Humans
(6)
Hematology, Oncology And Palliative Medicine
(5)
Anemia
(4)
Female
(4)
Male
(4)
Mpn
(4)
Multiple Myeloma
(4)
Myelofibrosis
(4)
Adult
(3)
Aged
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Middle Aged
(3)
Momelotinib
(3)
Aged, 80 And Over
(2)
Anemia - Etiology
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Clinical Lymphoma Myeloma & Leukemia/clinical Lymphoma, Myeloma And Leukemia
(14)

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation–Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study

MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Serum Free Light Chain Difference and β 2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis

Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing

P-217: First line daratumumab-VTd versus VRd for transplant eligible multiple myeloma

Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma

P-200: Pomalidomide-based chemotherapy in plasmacytoma at relapse

P-429 Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia

OA-25 Impact of Clonal Hematopoiesis on the Carcinogenic Process of Multiple Myeloma

P-052 LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)

P-135 Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean multiple myeloma working party (KMM 2202)

Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma

MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up

Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

P-284 Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)

P-144 Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Poster: MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Poster: MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Aktive Filter

Suchergebnisse filtern